Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Registration Number
- NCT02171156
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
1199.177.1003 Boehringer Ingelheim Investigational Site
🇺🇸Winter Park, Florida, United States
1199.177.1012 Boehringer Ingelheim Investigational Site
🇺🇸Skokie, Illinois, United States
1199.177.1014 Boehringer Ingelheim Investigational Site
🇺🇸Muncie, Indiana, United States
1199.177.1002 Boehringer Ingelheim Investigational Site
🇺🇸Minneapolis, Minnesota, United States
1199.177.1011 Boehringer Ingelheim Investigational Site
🇺🇸Charleston, South Carolina, United States
1199.177.1022 Boehringer Ingelheim Investigational Site
🇺🇸Spartanburg, South Carolina, United States
1199.177.1067 Boehringer Ingelheim Investigational Site
🇺🇸Houston, Texas, United States
1199.177.1003 Boehringer Ingelheim Investigational Site🇺🇸Winter Park, Florida, United States